The dropout rate for patients on Gilead Sciences’ hepatitis C treatment Sovaldi is quadruple what was seen during clinical trials, data showed Wednesday. CVS Health (CVS) Research Institute researchers found that real-world use of Gilead’s (GILD) blockbuster drug reflects an 8.1% discontinuation rate vs. an approximate 2% rate in trials. The study also found that patients new to the hepatitis C treatment were less likely to complete
Gilead Sciences (GILD) shares are backsliding Wednesday on news that the patient drop-out rate for hepatitis C drug Sovaldi is quadruple that of clinical trials. In addition, the biotech’s Phase 2 study results that show its pancreatic cancer treatment failed to show any clinical benefits to patients. Shares of Gilead fell 1.8% to 102.84 in afternoon trading on the stock market today. The stock hit a record 110.84 on Sept. 3. CVS Health Research
Gilead Sciences (GILD) stock was rebounding in afternoon trading on the stock market today, as an analyst lifted his Q3 forecast for sales of blockbuster hepatitis C drug Sovaldi. FBR analyst Andrew Berens raised his estimate to $2.24 billion from $1.94 billion after examining August prescription data from health industry research firm Symphony Health Solutions. After a record-breaking launch following U.S. approval last December, Sovaldi’s sales